Total Payments
$453,983
2024 Payments
$156,043
Companies
39
Transactions
596
Medicare Patients
14,211
Medicare Billing
$9.1M
Payment Breakdown by Category
Other$290,200 (63.9%)
Consulting$82,827 (18.2%)
Travel$49,104 (10.8%)
Food & Beverage$22,322 (4.9%)
Research$9,480 (2.1%)
Education$31.10 (0.0%)
Gifts$19.40 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $279,148 | 59 | 61.5% |
| Consulting Fee | $82,827 | 35 | 18.2% |
| Travel and Lodging | $49,104 | 136 | 10.8% |
| Food and Beverage | $22,322 | 353 | 4.9% |
| Unspecified | $9,480 | 2 | 2.1% |
| Honoraria | $7,551 | 8 | 1.7% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $3,500 | 1 | 0.8% |
| Education | $31.10 | 1 | 0.0% |
| Gift | $19.40 | 1 | 0.0% |
Payments by Type
General
$444,503
594 transactions
Research
$9,480
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $299,534 | 242 | $0 (2024) |
| Genentech USA, Inc. | $85,356 | 118 | $0 (2024) |
| F. Hoffmann-La Roche AG | $18,557 | 7 | $0 (2020) |
| Allergan, Inc. | $9,902 | 33 | $0 (2022) |
| Alimera Sciences, Inc. | $8,127 | 33 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $7,810 | 7 | $0 (2024) |
| Genentech, Inc. | $5,405 | 12 | $0 (2019) |
| NotalVision | $4,048 | 11 | $0 (2019) |
| Carl Zeiss Meditec, Inc. | $3,728 | 2 | $0 (2017) |
| Alcon Vision LLC | $2,877 | 29 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $156,043 | 163 | Regeneron Healthcare Solutions, Inc. ($128,542) |
| 2023 | $150,525 | 147 | Regeneron Healthcare Solutions, Inc. ($120,046) |
| 2022 | $42,068 | 52 | Genentech USA, Inc. ($27,447) |
| 2021 | $23,717 | 32 | Regeneron Healthcare Solutions, Inc. ($21,074) |
| 2020 | $15,258 | 23 | F. Hoffmann-La Roche AG ($9,330) |
| 2019 | $33,482 | 66 | Regeneron Healthcare Solutions, Inc. ($10,286) |
| 2018 | $16,182 | 61 | Genentech USA, Inc. ($5,238) |
| 2017 | $16,708 | 52 | Allergan Inc. ($7,298) |
All Payment Transactions
596 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $4.50 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/12/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,640.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/08/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $22.22 | General |
| Category: Ophthalmology | ||||||
| 12/07/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $119.76 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/06/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $3,290.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/06/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $2,350.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/01/2024 | Apellis Pharmaceuticals, Inc. | — | Honoraria | Cash or cash equivalent | $378.00 | General |
| 11/22/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $39.86 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/19/2024 | Genentech USA, Inc. | Susvimo (Drug) | Food and Beverage | In-kind items and services | $19.72 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/18/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $24.41 | General |
| Category: Ophthalmology | ||||||
| 11/14/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $23.81 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/13/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $82.44 | General |
| Category: Ophthalmology | ||||||
| 11/13/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $30.73 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/06/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $24.45 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/31/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $9,400.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/29/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Travel and Lodging | In-kind items and services | $322.08 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/29/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Travel and Lodging | In-kind items and services | $308.42 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/29/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Travel and Lodging | In-kind items and services | $263.38 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/29/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Travel and Lodging | In-kind items and services | $261.46 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/26/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Travel and Lodging | In-kind items and services | $352.28 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/26/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Travel and Lodging | In-kind items and services | $167.98 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/26/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $126.02 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/25/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Travel and Lodging | In-kind items and services | $168.48 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/08/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,640.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/02/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $110.07 | General |
| Category: OPHTHALMOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| HARBOR 1 | F. Hoffmann-La Roche AG | $9,330 | 1 |
| A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | Regeneron Pharmaceuticals, Inc. | $149.60 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 4,498 | 55,574 | $9.0M | $4.0M |
| 2022 | 24 | 4,641 | 16,651 | $5.6M | $2.6M |
| 2021 | 21 | 2,606 | 7,458 | $2.9M | $1.5M |
| 2020 | 21 | 2,466 | 6,019 | $2.0M | $1.0M |
Total Patients
14,211
Total Services
85,702
Medicare Billing
$9.1M
Procedure Codes
91
All Medicare Procedures & Services
91 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 129 | 1,829 | $2.3M | $1.3M | 55.2% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 74 | 39,540 | $1.7M | $1.2M | 66.1% |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | Office | 2023 | 55 | 1,312 | $653,000 | $287,671 | 44.1% |
| J3490 | Unclassified drugs | Office | 2023 | 44 | 1,166 | $746,050 | $278,897 | 37.4% |
| 67028 | Injection of drug into eye | Office | 2023 | 257 | 2,224 | $1.4M | $224,531 | 15.5% |
| Q5124 | Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | Office | 2023 | 48 | 807 | $403,500 | $144,081 | 35.7% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 626 | 1,119 | $195,735 | $125,841 | 64.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 558 | 1,149 | $229,800 | $125,776 | 54.7% |
| 92134 | Imaging of retina | Office | 2023 | 934 | 3,483 | $522,230 | $124,447 | 23.8% |
| 92242 | Exam of retinal blood vessels and blood vessels between the white part of eye and retina using a special camera after injection of a dye | Office | 2023 | 242 | 309 | $154,500 | $73,110 | 47.3% |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2023 | 18 | 480 | $168,000 | $57,773 | 34.4% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 270 | 668 | $100,200 | $54,744 | 54.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 295 | 295 | $81,125 | $40,170 | 49.5% |
| 92287 | Imaging of front third of eye using a special camera after injection of a dye | Office | 2023 | 105 | 137 | $39,045 | $18,705 | 47.9% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 74 | 87 | $25,010 | $10,815 | 43.2% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 345 | 423 | $35,955 | $8,947 | 24.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 77 | 94 | $14,100 | $7,503 | 53.2% |
| 67145 | Photocoagulation treatment to prevent detachment of retina | Office | 2023 | 22 | 28 | $98,000 | $6,129 | 6.3% |
| 92250 | Photography of the retina | Office | 2023 | 116 | 141 | $24,611 | $4,545 | 18.5% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 61 | 112 | $39,200 | $4,287 | 10.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 20 | 20 | $7,000 | $3,541 | 50.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 13 | 18 | $6,533 | $1,410 | 21.6% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2023 | 85 | 95 | $7,125 | $1,233 | 17.3% |
| 92083 | Exam of visual field with extended testing | Office | 2023 | 17 | 18 | $4,950 | $897.00 | 18.1% |
| 92134 | Imaging of retina | Facility | 2023 | 13 | 20 | $1,720 | $433.80 | 25.2% |
About Dr. Michael Javaheri, M.D
Dr. Michael Javaheri, M.D is a Ophthalmology healthcare provider based in Beverly Hills, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/29/2008. The National Provider Identifier (NPI) number assigned to this provider is 1124298575.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Javaheri, M.D has received a total of $453,983 in payments from pharmaceutical and medical device companies, with $156,043 received in 2024. These payments were reported across 596 transactions from 39 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($279,148).
As a Medicare-enrolled provider, Javaheri has provided services to 14,211 Medicare beneficiaries, totaling 85,702 services with total Medicare billing of $9.1M. Data is available for 4 years (2020–2023), covering 91 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Retina Specialist
- Location Beverly Hills, CA
- Active Since 02/29/2008
- Last Updated 12/06/2023
- Taxonomy Code 207W00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1124298575
Products in Payments
- EYLEA HD (Biological) $213,073
- EYLEA (Biological) $93,416
- Vabysmo (Drug) $38,981
- Lucentis (Biological) $35,674
- VABYSMO (Drug) $27,305
- OZURDEX (Drug) $9,550
- Iluvien (Drug) $6,790
- ForeseeHome (Device) $4,048
- Constellation (Device) $3,783
- ACTHAR (Biological) $2,648
- Syfovre (Drug) $990.07
- EYLEA AFLIBERCEPT INJECTION (Biological) $855.20
- YUTIQ (Drug) $359.60
- LOTEMAX SM (Drug) $337.92
- NGENUITY (Device) $278.07
- Implantable Miniature Telescope (Device) $241.42
- CIRRUS HD-OCT (Device) $227.57
- BEOVU (Drug) $213.65
- ILUVIEN (Drug) $213.15
- DEXYCU (Drug) $173.77
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Beverly Hills
Dr. Raymond Douglas, Md, Phd, MD, PHD
Ophthalmology — Payments: $1.3M
Ophthalmology $1.3M
Stuart Stoll, Md, MD
Ophthalmology — Payments: $1.2M
Ophthalmology $1.2M
Kerry Assil, M.d, M.D
Ophthalmology — Payments: $378,371
Ophthalmology $378,371
Afshin Khodabakhsh, Md, MD
Ophthalmology — Payments: $158,563
Ophthalmology $158,563
Christopher Zoumalan, M.d, M.D
Ophthalmology — Payments: $156,708
Ophthalmology $156,708
Dr. Jillian Chong, M.d, M.D
Ophthalmology — Payments: $58,972
Ophthalmology $58,972